Maxim Pharmaceuticals Inc. (MAXM; SSE:MAXM) believes that its Maxamine histamine immune stimulant ultimately will enjoy a broad label to treat stage IV melanoma, despite hitting the primary end point only in a subgroup of its Phase III patient population.

The company's U.S. study compared Maxamine plus IL-2 with IL-2 alone. In the overall population of 305 patients with stage IV melanoma, the median survival of the Maxamine group was 272 days versus 245 days for IL-2 patients, not